Skip to main content
. 2023 Apr 22;11(5):883. doi: 10.3390/vaccines11050883

Table 1.

Characteristics of the study group by stage of the study.

Variable Stage 1
(n = 1340)
Stage 2
(n = 769)
Stage 3
(n = 138)
p
Age 18–29 133 10% 47 6% 15 11% p < 0.001
30–39 305 23% 146 19% 43 31%
40–49 327 24% 240 31% 36 26%
50–59 333 25% 238 31% 26 19%
>60 242 18% 98 13% 18 13%
Sex Male 391 29% 247 32% 29 21% p = 0.025
Female 949 71% 522 68% 109 79%
Place of residence Village 239 18% 119 15% 25 18% p = 0. 004
<50,000 125 9% 75 10% 6 4%
50–100 thousand 35 3% 18 2% 3 2%
100–500 thousand 87 6% 28 4% 1 1%
>500,000 854 64% 529 69% 103 75%
Education Basic 12 1% 10 1% 0 0% p = 0.008
Medium 428 32% 220 29% 39 28%
Professional 84 6% 58 8% 0 0%
Higher 816 61% 481 63% 99 72%
Are they a healthcare worker? Yes 1252 93% 685 89% 134 97% p < 0.001
Not 88 7% 84 11% 4 3%
Chronic diseases Hypertension - - - - 19 14%
Type 1 diabetes - - - - 0 0%
Type 2 diabetes - - - - 11 8%
Obesity - - - - 14 10%
COPD - - - - 0 0%
Recurrent respiratory tract infections - - - - 0 0%
Bronchial asthma - - - - 8 6%
Heart diseases - - - - 8 6%
Cancer - - - - 1 1%
Other - - - - 3 2%

Abbreviations: ‘-’—lack of data.